7 research outputs found
Production of human recombinant proapolipoprotein A-I in Escherichia coli: purification and biochemical characterization
A human liver cDNA library was used to isolate a clone coding for apolipoprotein A-I (Apo A-I). The clone
carries the sequence for the prepeptide (18 amino acids), the propeptide (6 amino acids), and the mature protein
(243 amino acids). A coding cassette for the proapo A-I molecule was reconstructed by fusing synthetic
sequences, chosen to optimize expression and specifying the amino-terminal methionine and amino acids -6
to +14, to a large fragment of the cDNA coding for amino acids 15-243. The module was expressed in
pOTS-Nco, an Escherichia coli expression vector carrying the regulatable X P^ promoter, leading to the production
of proapolipoprotein A-I at up to 10% of total soluble proteins. The recombinant polypeptide was
purified and characterized in terms of apparent molecular mass, isoelectric point, and by both chemical and
enzymatic peptide mapping. In addition, it was assayed in vitro for the stimulation of the enzyme lecithin:
cholesterol acyltransferase. The data show for the first time that proapo A-I can be produced efficiently in
E. coli as a stable and undegraded protein having physical and functional properties indistinguishable from
those of the natural product
JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs
BACKGROUND: Microsomal transfer protein inhibitors (MTPi) have the potential to be used as a drug to lower plasma lipids, mainly plasma triglycerides (TG). However, studies with animal models have indicated that MTPi treatment results in the accumulation of hepatic TG. The purpose of this study was to evaluate whether JTT-130, a unique MTPi, targeted to the intestine, would effectively reduce plasma lipids without inducing a fatty liver. METHODS: Male guinea pigs (n = 10 per group) were used for this experiment. Initially all guinea pigs were fed a hypercholesterolemic diet containing 0.08 g/100 g dietary cholesterol for 3 wk. After this period, animals were randomly assigned to diets containing 0 (control), 0.0005 or 0.0015 g/100 g of MTPi for 4 wk. A diet containing 0.05 g/100 g of atorvastatin, an HMG-CoA reductase inhibitor was used as the positive control. At the end of the 7(th )week, guinea pigs were sacrificed to assess drug effects on plasma and hepatic lipids, composition of LDL and VLDL, hepatic cholesterol and lipoprotein metabolism. RESULTS: Plasma LDL cholesterol and TG were 25 and 30% lower in guinea pigs treated with MTPi compared to controls (P < 0.05). Atorvastatin had the most pronounced hypolipidemic effects with a 35% reduction in LDL cholesterol and 40% reduction in TG. JTT-130 did not induce hepatic lipid accumulation compared to controls. Cholesteryl ester transfer protein (CETP) activity was reduced in a dose dependent manner by increasing doses of MTPi and guinea pigs treated with atorvastatin had the lowest CETP activity (P < 0.01). In addition the number of molecules of cholesteryl ester in LDL and LDL diameter were lower in guinea pigs treated with atorvastatin. In contrast, hepatic enzymes involved in maintaining cholesterol homeostasis were not affected by drug treatment. CONCLUSION: These results suggest that JTT-130 could have potential clinical applications due to its plasma lipid lowering effects with no alterations in hepatic lipid concentrations